| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > Basic Guidelines To Selecting Profitable Shares |
|
Top Articles - Basic Guidelines To Selecting Profitable Shares
If you want to become a successful, profitable share trader in the stock market, you need to implement a few basic guidelines. Lis According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ted below are a few ideas you might find invaluable. 1. Adhere to your written down plan for buying and selling shares. I.e. The a ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ount you are going to spend, the amount you can afford to lose if things go the wrong way (2% of the total value is a good guidelin lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ) The % profit you want to make, after allowing for brokerage etc. The time frame you would like. (Not always possible) for the t here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe tal transaction. Is it short, medium or long term? The number of shares you want. (This depends also on your capital constraints.) d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro Diversify don’t invest just in one area. Spread your risk over different types of companies. 2. The last high in the share price ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc have all been higher that the one the day before. Do this for a minimum of three days to five days consecutively.] 3. Plenty of li easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi uidity meaning a good volume of shares has exchanged hands recently. 4. Buyers outnumber sellers. If the other way round, the shar nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically price will drop downwards for sure. 5. Recent news or rumours of news .i.e. Takeovers, profits etc. Only good news of course. 6. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ Directors buying shares {not selling} in the last 2 to 3 weeks. 7. The “Trend Lines” show a definite trend upwards. If in doubt do ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ’t trade. 8. A visual look {the old “eye ball test”} at the most recent chart, preferably over the last month’s performance. Agai ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a n if in any doubt drop the share till next time; just add it to your watch list. I have around 30 to 40 companies currently on my dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod atch list. I whittle them down to around 3 -4 using those basic criteria above. It is not a hard a fast criteria, make up some of cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin our own preferences.
Mine is just to give you a very basic idea to help you get started. The Law of Probabilities. When it all tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen oils down to it, there are no guarantees we are just working on the “Probability” of the share price going upwards. NB If the shar t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel is going “Sideways” it is only 50- 50 probability .don’t bother this is a share going sideways and you might as well toss a coin b ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ecause you are now gambling. Wait a few days and review it then. If a share is going “Downwards” I use the probability of 70% of y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products t continuing that way, 20 % chance of going sideways, 10% going upwards. The next probability I use for an “Upwards” moving share . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de rice is 70% to continue upwards and 10% probability of going sideways and 20% probability of it downwards. Remember these are only elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip guidelines; if things don’t go to plan that is when you implement a “stop loss” {see past article if you want to know more on this. tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Manufacturing Your Products In China For Your Home Based Business The Pay-Per-Click Customer's Bill Of Rights Finance Options for Debt Consolidation
|